Sofinnova Partners

SafeHeal is a medical device company specializing in digestive surgery. It develops and manufactures a vacuum-based, flexible bypass sheath designed to protect a gastrointestinal anastomosis after colorectal cancer surgery, remaining in place during healing to reduce ostomy needs and support postoperative recovery. The company originated as the first venture created and incubated by MD Start, a medtech accelerator, with backing from MD Start and Sofinnova Partners.

Signadori Bio is a biopharmaceutical company dedicated to developing innovative cellular immunotherapy treatments for cancer. It operates in the cell and gene therapy space, aiming to advance novel approaches in oncology to help doctors combat cancer more effectively.

Forth Therapeutics is a biotechnology company specializing in the development of precision treatments for fibrotic diseases. The company employs advanced computational models and machine learning algorithms to integrate single cell and spatial genomics data, enabling it to identify antifibrotic targets with high precision. This approach allows Forth Therapeutics to create detailed maps of fibrotic diseases, accelerating the discovery and development of precision drugs.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

Latent Labs is a pioneering AI laboratory specializing in programmable biology. It develops advanced generative AI models that capture the core principles of biology, empowering healthcare partners to create novel antibodies, optimize existing enzymes, and advance genetic engineering. This enables partners to gain unparalleled control over molecular biology, driving transformative advancements in health and sustainability.

Berry Street specializes in online telehealth services for nutrition therapy. It connects patients with board-certified dietitians via video and chat platforms, covering areas such as disordered eating, heart health, PCOD, liver disease, women's health, sports nutrition, and diabetes. Berry Street is accepted by many insurance plans, making its services accessible to a wide range of individuals seeking to improve their health and quality of life.

Bioptimus develops a universal AI foundation model that connects biological data across different scales, from molecules to entire organisms. This enables clients to derive actionable insights and accelerate biomedical innovation.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.

nChroma Bio is a biotechnology company specializing in targeted genetic medicine. It operates an integrated product engine for safe, accurate, and targeted in vivo administration, aiming to overcome limitations of current genetic medicine techniques. The company focuses on liver-targeted therapies, initially for chronic hepatitis B and D, leveraging epigenetics to enable precise and specific gene regulation. This approach allows for therapies with programmable tissue specificity, potentially offering durable and targeted cures for the liver and other organs.

Founded in 2019, Noema Pharma is a biotechnology company based in Basel, Switzerland. It specializes in developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks, aiming to improve patient outcomes and quality of life.

Meiogenix is a biotechnology company developing breeding technologies to uncover unexplored genetic diversity in organisms, expanding natural biodiversity and enabling the development of products to address global food, climate, sustainability, and industrial challenges. It uses chromosome-editing-based approaches to modulate the frequency of homologous recombination in eukaryotic cells, enabling natural breeding and delivering new products for farmers and industry.

Elicit Plant is an agro-biotech company focused on enhancing crop resilience to water scarcity. It develops innovative phytosterol-based solutions that significantly reduce water stress in plants, enabling them to better withstand drought conditions.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Purespring Therapeutics specializes in developing gene therapies targeting kidney diseases, focusing on podocytes, specialized kidney cells. It is one of the first globally to use AAV gene therapy specifically for kidney conditions.

Genespire is a biotechnology company dedicated to developing innovative gene therapies for patients suffering from genetic diseases, with a particular emphasis on primary immunodeficiencies and inherited metabolic disorders. The company specializes in creating therapies that utilize integration-defective lentiviral vectors combined with gene editing techniques. This approach allows for highly effective and adaptable targeted insertion of therapeutic genes into blood cells, providing patients with a range of tailored therapeutic options suited to their specific conditions. By focusing on transformative solutions, Genespire aims to significantly improve the lives of individuals affected by severe genetic disorders.

NOVAMEAT develops plant-based meat substitutes using proprietary micro-extrusion technology. Their products aim to replicate the texture, appearance, taste, and nutritional properties of animal meat, promoting a sustainable and efficient food supply system.

deepc GmbH, based in Munich, Germany, specializes in artificial intelligence software for medical imaging, particularly in the field of radiology. The company has developed a disease-agnostic AI solution that screens medical imaging data in real-time, identifying healthy and non-healthy cases to prevent diagnostic errors. Its innovative web-based platform serves as a comprehensive operating system for diagnostics, allowing medical professionals and AI developers to seamlessly integrate diagnostic AI and other digital tools into clinical workflows. By enhancing the quality of diagnoses and improving cost-efficiency, deepc aims to facilitate immediate access to accurate diagnostics for individuals worldwide. The company has received recognition for its contributions to healthcare, including awards from the Federal Ministry for Economic Affairs and Energy.

Micropep Technologies is an agricultural biotechnology company founded in 2016 and based in Toulouse, France. The company specializes in the development of non-GMO bioherbicides and biostimulants utilizing its innovative miPEP technology, which harnesses naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep focuses on four key development programs: germination, flowering, growth, and weed control, aiming to improve agricultural yields while maintaining the integrity of plant DNA. By leveraging the potential of these biomimetic peptides, Micropep seeks to provide effective solutions for managing plant genetics and enhancing resistance to diseases, thereby supporting sustainable farming practices.

Asceneuron is a biotechnology company dedicated to discovering and developing therapeutics for neurodegenerative disorders with high unmet medical needs. It focuses on orphan tauopathies, Alzheimer's disease, and Parkinson's disease.

Endoron Medical is a company focused on developing innovative medical devices aimed at enhancing the treatment of abdominal aortic aneurysms. The company specializes in creating an endovascular suture and a fixation device for endografts, which are essential for patients undergoing endovascular aneurysm repair. By employing advanced technology, Endoron Medical aims to provide long-lasting sealing solutions that improve patient outcomes and support healthcare professionals in effectively managing this serious condition.

May Health is a healthcare company focused on addressing infertility related to Polycystic Ovary Syndrome (PCOS). The company has developed an innovative, minimally invasive procedure aimed at restoring ovulation in women with PCOS. This one-time treatment is performed transvaginally under ultrasound guidance, allowing for its execution in a clinical setting without the need for general anesthesia. May Health's approach seeks to provide patients with a more natural pregnancy experience by assisting the body to ovulate as it would naturally, thereby offering a less medicalized alternative to traditional fertility treatments.

Cure51 is a company focused on advancing cancer treatment through the development of a clinical and molecular database. Its primary mission is to create a comprehensive database of cancer survivors, utilizing their unique biological characteristics to identify potential drug targets. By analyzing the biology of long-term cancer survivors, Cure51 aims to aid healthcare researchers in decoding genetic information derived from biopsies, blood tests, imaging, and other samples. This innovative approach seeks to accelerate drug discovery, ultimately contributing to the formulation of new and effective cancer therapies.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Mainstay Medical is a medical device company focused on developing and commercializing ReActiv8, an implantable neurostimulation system designed to treat chronic mechanical low back pain by restoring control to the lumbar stabilizing muscles. Headquartered in Dublin, Ireland, it operates in Ireland, the United States, and Australia and collaborates with scientists and clinical experts to deliver therapies for the large underserved population of people with debilitating chronic low back pain. Founded in 2008, the company aims to provide a restorative treatment that improves function and quality of life by reestablishing muscle control in the lumbar spine.

Bioptimus develops a universal AI foundation model that connects biological data across different scales, from molecules to entire organisms. This enables clients to derive actionable insights and accelerate biomedical innovation.

Sensorion SA is a biopharmaceutical company based in Montpellier, France, focused on developing innovative therapies for inner ear disorders, particularly hearing loss and vestibular deficits. Founded in 2009, the company is engaged in clinical-stage research, with key products including SENS-111, currently in phase II trials for acute unilateral vestibulopathy, and SENS-401, which is in phase I trials for sudden sensorineural hearing loss. Additionally, Sensorion is advancing SENS-300 in pre-clinical development for inner ear toxicity treatment. The company also collaborates with Cochlear Limited to explore combination therapies for cochlear implant patients, aiming to enhance therapeutic outcomes. Sensorion's commitment to addressing inner ear health positions it as a significant player in the biopharmaceutical landscape.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

DISCO Pharmaceuticals is a biotechnology company focused on advancing cancer treatment through its innovative surfaceome mapping platform. The firm specializes in large-scale surfaceome unlocking of cancer cells, utilizing transformative cell discovery technology to identify proteins and protein communities present on the surface of cancer cells. This scalable approach allows for the extraction of comprehensive target information that traditional proteomics, genome, or transcriptome sequencing methods cannot provide. By leveraging this technology, DISCO Pharmaceuticals aims to enable the development of cancer-selective therapies, potentially enhancing treatment efficacy while minimizing side effects for patients.

Qorium is a biotechnology company that employs cell culturing and tissue engineering technologies to produce premium, real leather. Its sustainable, collagen-based leather aims to minimize environmental impact by being independent of the meat industry and deforestation.

GlycoEra is a biotechnology company focused on developing novel therapeutics by harnessing the power of glycan-mediated biology.

Freya Biosciences is a clinical-stage company specializing in women's health. It develops microbial immunotherapies, focusing on unmet needs across various indications.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

T-Therapeutics is a biopharmaceutical company focused on developing engineered soluble biologics for oncological and immunological applications. The company utilizes a proprietary T cell receptor (TCR) discovery platform based on a highly humanized mouse model, which allows access to TCRs for human antigens that are typically unavailable from human samples. This innovative approach enables the binding of specific peptide-MHC (pMHC) targets on cells, facilitating the recruitment of T cells to combat cancer or modulate immune responses. Through its advanced capabilities in mouse genome engineering, single-cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance the quality of life for patients suffering from chronic and infectious diseases. The company's culture emphasizes creativity and collaboration, fostering an environment conducive to groundbreaking research and development in the biopharmaceutical field.

Founded in Seattle in 2008, Arzeda specializes in protein design technology. It creates and manufactures proteins and enzymes for pharmaceuticals, industrial chemicals, polymers, and other advanced applications.

l'école AI is a computer vision-focused development platform. Its objective is to enable humans to use AI with purpose to change the future, beginning with a focus on speeding advances in life sciences using computer vision.

Betteromics is a SaaS platform empowering life sciences professionals with AI-driven computational techniques. It integrates seamlessly within clients' Virtual Private Clouds, connecting diverse data sources and providing a centralized, objective data hub. The platform accelerates precision biomarker discovery and clinical research by managing large, complex molecular datasets securely.

Bon Vivant is a French biotechnology startup co-founded by Hélène Briand and Stéphane Mac Millan. The company specializes in the development of plant-based milk and dairy alternatives using precision fermentation technology. By employing yeast to create non-dairy products that closely mimic the texture and taste of traditional dairy, Bon Vivant aims to provide accessible and high-quality alternatives to conventional milk proteins. Their innovative approach involves cultivating milk proteins in a vegetable culture medium, allowing for the fermentation process that yields pure milk protein substitutes suitable for cheese and other dairy items. Through its efforts, Bon Vivant addresses the growing demand for sustainable and plant-based food options.

Sitryx Therapeutics is a biopharmaceutical company based in Oxford, United Kingdom, established in 2018. The company specializes in developing disease-modifying therapeutics that target immuno-oncology and immuno-inflammation by regulating cell metabolism. Through its innovative approach, Sitryx aims to correct and alter immune cell functions to inhibit tumor growth. Co-founded by a team of renowned scientists from both the United States and Europe, Sitryx is committed to advancing the field of immunometabolism. The company has a diverse pipeline of projects at various stages of drug discovery, supported by significant investments from a syndicate of specialist investors.

Gradient Denervation Technologies develops an endovascular catheter-based medical device designed to treat pulmonary hypertension by reducing pulmonary vascular resistance and improving cardiovascular hemodynamics. Founded in 2019, the company is headquartered in Paris, France.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Sensorion SA is a biopharmaceutical company based in Montpellier, France, focused on developing innovative therapies for inner ear disorders, particularly hearing loss and vestibular deficits. Founded in 2009, the company is engaged in clinical-stage research, with key products including SENS-111, currently in phase II trials for acute unilateral vestibulopathy, and SENS-401, which is in phase I trials for sudden sensorineural hearing loss. Additionally, Sensorion is advancing SENS-300 in pre-clinical development for inner ear toxicity treatment. The company also collaborates with Cochlear Limited to explore combination therapies for cochlear implant patients, aiming to enhance therapeutic outcomes. Sensorion's commitment to addressing inner ear health positions it as a significant player in the biopharmaceutical landscape.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

Crescendo Biologics develops innovative antibody therapeutics using its proprietary platforms. The company focuses on generating high-affinity, human VH antibody fragments for oncology and other indications. Its technology is based on a transgenic mouse platform that enables the creation of fully human VHH domain building blocks.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.

AAVantgarde Bio is a biotechnology company focused on developing gene therapies for inherited retinal disorders. It builds on proprietary Adeno-Associated Virus vector platforms designed to overcome cargo capacity limits of standard AAV vectors, enabling delivery of large genes to ocular tissues and other tissues in vivo, with the aim of treating genetic eye diseases and related conditions.

BrightHeart is a medical technology startup that is developing artificial intelligence software to help diagnose congenital heart abnormalities in foetuses.

TISSIUM is a medical device company headquartered in Paris, France, focused on the development and commercialization of innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, provide strong adhesion to tissues, and enable rapid wound closure in the body's dynamic environments. TISSIUM leverages advanced research and intellectual property from renowned laboratories, including those of Robert Langer at MIT and Jeff Karp at Brigham and Women’s Hospital. Its technology platform includes a proprietary family of fully biosynthetic, biomorphic, and programmable polymers, which are tailored for tissue reconstruction across various clinical applications. Founded in 2013, TISSIUM is supported by leading healthcare investors and aims to address unmet clinical needs through its groundbreaking approach to wound management.

Moon Surgical is a medical device company focused on enhancing minimally invasive surgical procedures through advanced robotics. The company is developing the Maestro System, a surgical robot designed to assist in laparoscopy by improving access to these techniques and optimizing the use of resources in the operating room. This technology provides surgeons with enhanced control and adaptability to various surgical conditions, thereby increasing efficiency and improving patient care. Moon Surgical's devices facilitate the stabilization and automatic positioning of endoscopes, as well as organ retraction, while maintaining the traditional surgical workflow. Through its innovative approach, Moon Surgical aims to transform surgical practices and enhance the overall surgical experience for both surgeons and patients.

Werewool develops a fiber development platform that creates biodegradable fibers for sustainable textiles. These fibers have inherent properties such as color, moisture management, and stretch, enabling the fashion industry to design apparel with reduced environmental impact.

Alia Therapeutics develops gene-editing medicines to treat rare genetic diseases. It focuses on next-generation CRISPR technologies that expand targetable genomic sites and improve modification precision, enabling therapies with greater specificity and safety that address genetic disorders at their roots.

Kiro develops an AI-powered digital health platform that enhances the relevance of lab test results for healthcare professionals and patients. Its tool provides personalized, understandable interpretations of medical biology reports using artificial intelligence to aid clinical decision-making, engage patients, and improve healthcare outcomes.

deepc GmbH, based in Munich, Germany, specializes in artificial intelligence software for medical imaging, particularly in the field of radiology. The company has developed a disease-agnostic AI solution that screens medical imaging data in real-time, identifying healthy and non-healthy cases to prevent diagnostic errors. Its innovative web-based platform serves as a comprehensive operating system for diagnostics, allowing medical professionals and AI developers to seamlessly integrate diagnostic AI and other digital tools into clinical workflows. By enhancing the quality of diagnoses and improving cost-efficiency, deepc aims to facilitate immediate access to accurate diagnostics for individuals worldwide. The company has received recognition for its contributions to healthcare, including awards from the Federal Ministry for Economic Affairs and Energy.

Mediar Therapeutics is a pre-clinical stage biotechnology company focused on developing therapeutics to treat fibrosis in chronically damaged organs. It designs antibodies that neutralize mediators driving fibrotic activity with the aim of halting and reversing fibrosis to improve patient outcomes. Founded in 2019 and based in Cambridge, Massachusetts, the company targets key fibrotic mediator proteins to address late-stage disease with precision and efficacy.

Nuage Therapeutics is a pharmaceutical company specializing in the development of selective drugs targeting proteins with disordered regions. It employs chemical biology and biomolecular condensation to create innovative treatments for challenging indications, focusing on intrinsically disordered targets to address unmet medical needs.

Founded in 2019, Noema Pharma is a biotechnology company based in Basel, Switzerland. It specializes in developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks, aiming to improve patient outcomes and quality of life.

Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

Abivax is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize immune responses in autoimmune and inflammatory diseases. Its portfolio aims to address large unmet needs across autoimmune conditions, viral infections, and cancer, with obefazimod in Phase 3 trials for adults with moderately to severely active ulcerative colitis, an inflammatory bowel disease. The company relies on its drug development platforms to advance treatments that modulate the immune system and potentially extend benefits to other inflammatory indications.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

EnginZyme is a Swedish biotechnology company established in 2014. It specializes in sustainable biomanufacturing, providing green chemistry solutions to various industries such as pharmaceuticals, food, chemicals, flavors, and fragrances. The company's patented cell-free technology platform enables the production of sustainable alternatives to plastics, nylons, rubbers, and other synthetics.

Microphyt is a company focused on researching, developing, producing, and marketing natural algae-based products. It specializes in creating bioactive dietary supplements aimed at promoting weight loss and supporting brain health. The company utilizes an industrial-scale supply of microalgae biomass and extracts, ensuring the preservation of cell integrity while achieving commercial quantities of slow-growing or biofilm-forming species. This approach enables Microphyt to effectively cater to the demands of healthcare industries, particularly in the personal care and food sectors.

Mablink Bioscience is a biotechnology company focused on developing a new class of cancer therapies known as Antibody Drug Conjugates (ADCs). The company specializes in designing homogeneous, plasma-stable ADCs that maintain their original pharmacological properties while achieving a high drug-to-antibody ratio (DAR). This innovative approach aims to provide healthcare professionals with enhanced treatment options for cancer patients, ultimately improving therapeutic outcomes.

Abivax is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize immune responses in autoimmune and inflammatory diseases. Its portfolio aims to address large unmet needs across autoimmune conditions, viral infections, and cancer, with obefazimod in Phase 3 trials for adults with moderately to severely active ulcerative colitis, an inflammatory bowel disease. The company relies on its drug development platforms to advance treatments that modulate the immune system and potentially extend benefits to other inflammatory indications.

F2G Ltd is a biotechnology company focused on developing innovative therapies for serious fungal infections. Founded in 1998 and based in Manchester, United Kingdom, F2G primarily works on its F3 series of anti-mold compounds, specifically targeting antifungal agents against Aspergillus and other filamentous molds. Utilizing proprietary genomics technology known as MycoBank, the company identifies essential gene targets in fungi, which informs its drug development process. F2G has diversified its approach to include chemistry-driven discovery, leveraging a strong development team to advance its patented compounds. The company's efforts aim to address difficult-to-treat fungal pathogens that pose significant mortality risks, particularly for immunocompromised patients, thereby enhancing treatment options in the pharmaceutical industry.

Inspirna is a clinical-stage biopharmaceutical company focused on developing innovative drug candidates that target essential drivers of cancer. Utilizing a discovery platform centered on RNA biology, Inspirna identifies novel cancer targets that contribute to tumor growth and disease progression. The company is advancing several first-in-class oral small molecules, including RGX-202, aimed at treating patients with RAS mutant colorectal cancer, and RGX-104, which is in development for small cell lung cancer and non-small cell lung cancer. Through its microRNA-based target discovery approach, Inspirna seeks to provide effective treatment options for cancer patients by employing targeted therapies that leverage small molecules and biologics.

Biosyntia is a Danish biotechnology company that develops biocatalysts for fermentation-based production of fine chemicals, including natural active ingredients, vitamins, and other bioactives. It employs proprietary high-throughput screening and metabolic engineering to enable rapid creation of biocatalysts that convert feedstocks into complex compounds, with the goal of lower production costs and reduced environmental impact compared to conventional chemical synthesis. The company partners with manufacturers in flavors, fragrances, APIs, pigments, additives and related sectors to establish sustainable manufacturing processes with improved quality and traceability. Biosyntia operates from the Novo Nordisk Foundation Center for Biosustainability in Hørsholm, Denmark.

Micropep Technologies is an agricultural biotechnology company founded in 2016 and based in Toulouse, France. The company specializes in the development of non-GMO bioherbicides and biostimulants utilizing its innovative miPEP technology, which harnesses naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep focuses on four key development programs: germination, flowering, growth, and weed control, aiming to improve agricultural yields while maintaining the integrity of plant DNA. By leveraging the potential of these biomimetic peptides, Micropep seeks to provide effective solutions for managing plant genetics and enhancing resistance to diseases, thereby supporting sustainable farming practices.

Moon Surgical is a medical device company focused on enhancing minimally invasive surgical procedures through advanced robotics. The company is developing the Maestro System, a surgical robot designed to assist in laparoscopy by improving access to these techniques and optimizing the use of resources in the operating room. This technology provides surgeons with enhanced control and adaptability to various surgical conditions, thereby increasing efficiency and improving patient care. Moon Surgical's devices facilitate the stabilization and automatic positioning of endoscopes, as well as organ retraction, while maintaining the traditional surgical workflow. Through its innovative approach, Moon Surgical aims to transform surgical practices and enhance the overall surgical experience for both surgeons and patients.

GFBiochemicals is a pioneering company that specializes in the production of levulinic acid directly from biomass on a commercial scale. Founded in 2008 by a group of biobased chemical experts, the company aims to revolutionize the chemicals and biofuels market by replacing petroleum-based products with sustainable alternatives. Through partnerships with the University of Pisa and the Polytechnic University of Milan, GFBiochemicals has developed breakthrough production technologies showcased in their Caserta plant. This plant has been equipped with innovative conversion, recovery, and purification technology to support the company's mission of advancing sustainable and eco-friendly solutions in various market sectors.

Prometheus Materials develops bio-cement with zero carbon emissions, aiming to reduce global CO2 emissions and promote sustainability in construction.

LimFlow is a medical technology company focused on developing innovative solutions for treating end-stage chronic limb ischemia (CLI) patients. Its flagship product, the LimFlow System, utilizes a novel percutaneous procedure to restore blood flow to the ischemic foot by diverting blood around diseased arteries into the tibial vein. This approach is designed to provide an elevated flow of oxygenated blood, thereby alleviating ischemic pain, promoting wound healing, reducing the risk of amputations, and enhancing patient mobility. Currently approved for sale in CE-mark regulated markets, the LimFlow System is also undergoing investigational use in the United States, where it offers new hope to patients who have exhausted other revascularization options. LimFlow emphasizes a multi-disciplinary team approach to maximize the benefits of its technology.

Elicit Plant is an agro-biotech company focused on enhancing crop resilience to water scarcity. It develops innovative phytosterol-based solutions that significantly reduce water stress in plants, enabling them to better withstand drought conditions.

SafeHeal is a medical device company specializing in digestive surgery. It develops and manufactures a vacuum-based, flexible bypass sheath designed to protect a gastrointestinal anastomosis after colorectal cancer surgery, remaining in place during healing to reduce ostomy needs and support postoperative recovery. The company originated as the first venture created and incubated by MD Start, a medtech accelerator, with backing from MD Start and Sofinnova Partners.

Endoron Medical is a company focused on developing innovative medical devices aimed at enhancing the treatment of abdominal aortic aneurysms. The company specializes in creating an endovascular suture and a fixation device for endografts, which are essential for patients undergoing endovascular aneurysm repair. By employing advanced technology, Endoron Medical aims to provide long-lasting sealing solutions that improve patient outcomes and support healthcare professionals in effectively managing this serious condition.

Meiogenix is a biotechnology company developing breeding technologies to uncover unexplored genetic diversity in organisms, expanding natural biodiversity and enabling the development of products to address global food, climate, sustainability, and industrial challenges. It uses chromosome-editing-based approaches to modulate the frequency of homologous recombination in eukaryotic cells, enabling natural breeding and delivering new products for farmers and industry.

DMC Biotechnologies, Inc. is a biotechnology company based in Boulder, Colorado, that specializes in the development of bio-based products through microbial fermentation technology. Founded in 2014, the company focuses on engineering microbial hosts to produce a range of specialty chemicals, flavors, fragrances, nutraceuticals, natural products, and pharmaceuticals. DMC Biotechnologies employs its proprietary Dynamic Metabolic Control technology to enhance production efficiency, thereby reducing costs and accelerating the timeline from discovery to commercial performance. The company's innovative approach supports sustainability by utilizing lower energy and resource inputs in the manufacturing process.

HotSpot Therapeutics is a biotechnology startup based in Boston, Massachusetts, established in 2017. The company specializes in the development of allosteric therapies that target regulatory sites on proteins. Its innovative therapeutic platform is designed to identify hotspots and locate pathway treatments for cancer, metabolic disorders, and rare diseases. By leveraging a comprehensive database of hotspot structures and utilizing data science, HotSpot Therapeutics employs a multidisciplinary approach to drug discovery. This approach aims to enhance the effectiveness of treatments and improve patient outcomes across a range of conditions.

Synthace is a software company that develops tools for life sciences R&D, enabling automation, digitization, and optimization of biological experiments across health, pharmaceutical, food, energy, and industrial biotechnology sectors. Its cloud-based Antha platform lets users visually design, execute, and analyze biological workflows and automates processes to improve success rates. The platform digitizes experiments end to end, allowing researchers to plan reproducible experiments, simulate them, run them on automation equipment, and automatically structure data and metadata in a centralized workspace. It enables codeless reprogramming of liquid handling and supports multifactorial experimentation by connecting experimental data with other digital tools in the ecosystem. The software is browser-based, requires no coding, and aims to streamline lab workflows, improve data quality, and broaden the scope of experiments that can be conducted. The company operates globally from its base in London, with additional presence in the United States.

Home Biosciences is a European venture builder and accelerator focused on biotechnology, based in Paris, France, and founded in 2019.

GlycoEra is a biotechnology company focused on developing novel therapeutics by harnessing the power of glycan-mediated biology.

Nitrase Therapeutics is a biopharmaceutical company developing therapies against a novel class of enzymes called nitrases, initially focusing on Parkinson’s disease. Its proprietary platform enables the identification and targeting of these enzymes to potentially slow or halt disease progression.

Sphere Fluidics Limited is a life sciences company focused on developing innovative technologies for single-cell analysis and characterization. The company offers unique products and collaborative research and development services that aid in the discovery of new cell strains and molecules. Its cell analysis systems facilitate the screening and isolation of rare and valuable biological variants, catering to various applications in research, therapeutic development, bioproduction, and diagnostics. By streamlining these processes, Sphere Fluidics enables clients to reduce costs and time, thereby accelerating advancements in biological and biopharmaceutical discovery.

Mozart Therapeutics is a biotechnology company specializing in the development of disease-modifying therapies for autoimmune and inflammatory diseases. It focuses on creating first-in-class CD8 Treg modulators to restore long-term immune balance and prevent progressive damage caused by autoreactive immune responses.

Leucid Bio is a biotechnology company focused on developing cell therapies for refractory solid tumors. It translates over two decades of King's College London research in CAR-T therapies, led by an experienced management team with scientific and commercial expertise.

CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, founded in 2018. The company specializes in the development of innovative treatments for cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, an aldosterone synthase inhibitor aimed at addressing resistant hypertension and primary aldosteronism. By advancing its clinical candidates toward marketing approval, CinCor seeks to provide effective solutions for patients suffering from these conditions.

iOmx Therapeutics AG is a Munich-based company specializing in immuno-oncology target discovery and drug development. The company focuses on creating first-in-class cancer therapeutics that target novel immune checkpoint modulators present on tumor cells. Utilizing a proprietary siRNA-based screening technology, iOmx systematically analyzes human tumor cells to identify innovative therapeutic targets and understand their mechanisms of action. The company's approach is rooted in the principles of cancer immune-checkpoint therapy, which aims to overcome tumors' inherent resistance to immune attacks. This resistance is often mediated by cell surface molecules that inhibit T cell activation. By neutralizing these negative interactions, iOmx Therapeutics seeks to reactivate the host immune response, ultimately enhancing the effectiveness of cancer treatments.

TISSIUM is a medical device company headquartered in Paris, France, focused on the development and commercialization of innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, provide strong adhesion to tissues, and enable rapid wound closure in the body's dynamic environments. TISSIUM leverages advanced research and intellectual property from renowned laboratories, including those of Robert Langer at MIT and Jeff Karp at Brigham and Women’s Hospital. Its technology platform includes a proprietary family of fully biosynthetic, biomorphic, and programmable polymers, which are tailored for tissue reconstruction across various clinical applications. Founded in 2013, TISSIUM is supported by leading healthcare investors and aims to address unmet clinical needs through its groundbreaking approach to wound management.

Protera specializes in developing functional food ingredients through innovative protein engineering and artificial intelligence. The company employs a proprietary deep-learning algorithm to enhance the design and development of protein products and enzymes, allowing for rapid prediction of high-value ingredients. This technological approach aims to address ethical, environmental, and consumer health challenges by providing healthier and safer food options made from responsibly and sustainably produced ingredients. By streamlining the product development process, Protera helps its customers bring these functional ingredients to market more efficiently and cost-effectively, while also focusing on robust intellectual property and strategic partnerships to support its business objectives.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

Comet Biorefining, Inc. is a Canadian company specializing in the development of sustainable ingredients and products derived from agricultural waste. It focuses on producing high-quality cellulosic glucose syrup, which is generated through its proprietary technology that converts materials such as wood, wheat straw, bagasse, and corn stover. This innovative approach provides a cost-effective and stable alternative to traditional food sugar sources. In addition to glucose syrup, Comet Biorefining offers plant dietary fibers and animal nutrition products. The company also provides biomass conversion and pretreatment services, alongside a range of consulting and project development services aimed at enhancing process technology and business development within the renewable biofuels and biochemicals sectors. With a demonstrated capacity for production at a small scale, Comet is actively pursuing commercial scale-up and partnerships to further its impact in the renewables industry.

Muna Therapeutics is a biopharmaceutical company dedicated to discovering and developing therapies aimed at slowing or halting devastating neurodegenerative diseases such as Parkinson's, Alzheimer's, Frontotemporal Dementia, and Multiple Sclerosis.

Micropep Technologies is an agricultural biotechnology company founded in 2016 and based in Toulouse, France. The company specializes in the development of non-GMO bioherbicides and biostimulants utilizing its innovative miPEP technology, which harnesses naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep focuses on four key development programs: germination, flowering, growth, and weed control, aiming to improve agricultural yields while maintaining the integrity of plant DNA. By leveraging the potential of these biomimetic peptides, Micropep seeks to provide effective solutions for managing plant genetics and enhancing resistance to diseases, thereby supporting sustainable farming practices.

AAVantgarde Bio is a biotechnology company focused on developing gene therapies for inherited retinal disorders. It builds on proprietary Adeno-Associated Virus vector platforms designed to overcome cargo capacity limits of standard AAV vectors, enabling delivery of large genes to ocular tissues and other tissues in vivo, with the aim of treating genetic eye diseases and related conditions.

Alia Therapeutics develops gene-editing medicines to treat rare genetic diseases. It focuses on next-generation CRISPR technologies that expand targetable genomic sites and improve modification precision, enabling therapies with greater specificity and safety that address genetic disorders at their roots.

Mnemo Therapeutics is a biotechnology company developing immune-based therapies, including cell therapies. Its EnfiniT platform uses epigenetic variation and CAR-T precision genetic engineering technology to target tumorous epitopes across various cancers.

Mainstay Medical is a medical device company focused on developing and commercializing ReActiv8, an implantable neurostimulation system designed to treat chronic mechanical low back pain by restoring control to the lumbar stabilizing muscles. Headquartered in Dublin, Ireland, it operates in Ireland, the United States, and Australia and collaborates with scientists and clinical experts to deliver therapies for the large underserved population of people with debilitating chronic low back pain. Founded in 2008, the company aims to provide a restorative treatment that improves function and quality of life by reestablishing muscle control in the lumbar spine.

CorWave is a company focused on developing innovative implanted cardiac support devices aimed at improving the quality of life for patients suffering from heart failure. Its flagship product, the CorWave LVAD, employs a unique undulating disc wave pumping mechanism, which replaces traditional high-speed impellers used in current continuous flow rotary pumps. This design significantly reduces trauma to blood, thereby minimizing complications such as clotting and bleeding. The CorWave pump generates a pulsatile flow that closely resembles the natural heartbeat, addressing a key limitation of existing LVADs that provide only continuous flow. Additionally, the device's low power consumption and compact size facilitate its potential for complete implantation, enhanced by a wireless energy transfer system. Through these advancements, CorWave aims to alleviate the burdens associated with heart failure and invasive surgical procedures.

Founded in 2019, Noema Pharma is a biotechnology company based in Basel, Switzerland. It specializes in developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks, aiming to improve patient outcomes and quality of life.